囊腫纖維化市場規模、佔有率、成長分析（按治療、給藥途徑、藥物類別和地區）- 產業預測（2025 年至 2032 年）

預計 2023 年全球囊腫纖維化市場價值將達到 61 億美元，到 2032 年將達到 205 億美元，預測期內（2025-2032 年）的複合年成長率為 13%。

由於患病率上升、治療方案的進步、新生兒篩檢舉措的擴大以及人們對該疾病的認知不斷提高，全球囊腫纖維化市場預計將經歷顯著成長。不斷增加的研發力度以及強大的政府支持計畫導致囊腫纖維化跨膜傳導調節器 (CFTR)調變器激增。透過篩檢進行早期發現已顯著改善了治療效果。此外，人們擴大轉向針對突變的治療方法，而增加的醫療保健支出和有效的患者權益倡導工作為加強醫療服務提供了新的機會。吸入裝置和藥物配方的創新正在擴大治療選擇。然而，治療成本高、患者人數有限、開發時間長以及服務欠缺地區的准入問題等挑戰繼續影響著市場的發展。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 顧客購買行為分析

囊腫纖維化市場規模（依治療方法及複合年成長率）（2025-2032）

• 市場概覽
• 藥品
• 裝置

囊腫纖維化市場規模（依給藥途徑及複合年成長率）（2025-2032）

• 市場概覽
• 口服
• 吸入

囊腫纖維化市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概覽
• 胰酵素補充劑
• 黏液溶解劑、支氣管擴張劑
• 抗生素
• CFTR調變器

囊腫纖維化市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 按部門分類的公司佔有率分析
  • 收益同比對比（2022-2024 年）

主要企業簡介

• Vertex Pharmaceuticals Incorporated（United States）
• AbbVie Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Novartis AG（Switzerland）
• Gilead Sciences, Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Viatris Inc.（United States）
• Chiesi Farmaceutici SpA（Italy）
• Alcresta Therapeutics, Inc.（United States）
• Laurent Pharmaceuticals Inc.（Canada）
• Pulmocide Ltd.（United Kingdom）
• Zambon SpA（Italy）
• Sanofi SA（France）
• Translate Bio（United States）
• Armata Pharmaceuticals, Inc.（United States）

結論和建議

Global Cystic Fibrosis Market size was valued at USD 6.1 Billion in 2023 and is poised to grow from USD 6.7 Billion in 2024 to USD 20.5 Billion by 2032, growing at a CAGR of 13% during the forecast period (2025-2032).

The global cystic fibrosis market is poised for significant growth driven by rising incidence rates, advancements in therapeutic options, expanded newborn screening initiatives, and heightened awareness of the disease. Increased research and development efforts have led to a surge in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, alongside robust government support programs. Early detection through screening has notably improved treatment efficacy. Additionally, a shift towards mutation-specific therapies is gaining traction, while rising healthcare expenditures and effective patient advocacy initiatives present new opportunities for enhanced care delivery. Innovations in inhalation devices and drug formulations are expanding treatment options. However, challenges such as high treatment costs, limited patient populations, lengthy development timelines, and access issues in underdeveloped regions continue to impact market progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cystic Fibrosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cystic Fibrosis Market Segments Analysis

The global cystic fibrosis market is segmented by treatment method, route of administration, and drug class. Based on treatment methods, the market is segmented into medication and devices. Based on the route of administration, the market is segmented into oral and inhaled. Based on drug class, the market is segmented into pancreatic enzyme supplements, mucolytic, bronchodilators, antibiotics, and CFTR modulators. Based on region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa.

Driver of the Global Cystic Fibrosis Market

Advancements in genetic research and innovative therapies, particularly CFTR modulators, are significantly enhancing the health and longevity of individuals affected by cystic fibrosis. These modern treatments uniquely address the fundamental biological underpinnings of the disease rather than merely alleviating its symptoms or associated complications. This targeted approach not only promises better health outcomes but also fosters greater acceptance and integration of these therapies within healthcare systems globally. As the medical landscape evolves, the emphasis on treating the root cause of cystic fibrosis is set to propel increased demand for these transformative treatments, ultimately benefiting patients worldwide.

Restraints in the Global Cystic Fibrosis Market

The global market for cystic fibrosis is significantly hindered by the high costs associated with advanced therapies, particularly CFTR modulators, which are often prohibitive for patients. Many insurance providers show reluctance to offer coverage or reimbursements for these treatments, leading to limited access. This issue is particularly acute in low- and middle-income countries, where the lack of financial support contributes to substantially lower treatment rates. Consequently, these barriers to access stifle overall growth in the cystic fibrosis market, creating disparities in treatment availability and outcomes for patients across different regions.

Market Trends of the Global Cystic Fibrosis Market

The global cystic fibrosis market is witnessing significant transformation driven by advancements in gene editing technologies and innovative CFTR modulators. These emerging therapies target the root genetic causes of the disease, marking a shift from traditional treatment methods. Increased investments in research and development are fostering a wave of mutation-specific approaches, enabling tailored treatment options that cater to individual patient needs. This trend emphasizes a move towards long-term, personalized management strategies, enhancing patient outcomes and quality of life. As new therapeutic modalities continue to evolve, the market is poised for substantial growth and expansion, attracting interest from various stakeholders across the healthcare landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Cystic Fibrosis Market Size by Treatment Method & CAGR (2025-2032)

• Market Overview
• Medication
• Devices

Global Cystic Fibrosis Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Inhaled

Global Cystic Fibrosis Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Pancreatic Enzyme Supplements
• Mucolytic, Bronchodilators
• Antibiotics
• CFTR Modulators

Global Cystic Fibrosis Market Size & CAGR (2025-2032)

• North America (Treatment Method, Route of Administration, Drug Class)
  • US
  • Canada
• Europe (Treatment Method, Route of Administration, Drug Class)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Method, Route of Administration, Drug Class)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Method, Route of Administration, Drug Class)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Method, Route of Administration, Drug Class)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Vertex Pharmaceuticals Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi Farmaceutici S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcresta Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laurent Pharmaceuticals Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pulmocide Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zambon S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Translate Bio (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Armata Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations